Dr. Reddy’s reported healthy set of numbers for the quarter, it was in-line on revenue and EBITDA fronts, but ahead on the PAT front. Company reported revenue growth of 13.4% yoy to Rs4,029.6cr, broadly in-line with consensus estimates. Due to lower selling and other expenses, EBITDA reported 45.3% yoy growth to Rs818.9cr, in-line with estimates. EBITDA margins stood at 20.3%, 446bps expansion on yoy basis. Led by strong EBITDA growth, company reported PAT of Rs455.4cr, 67.4% yoy growth and ~9% ahead of consensus estimates.
Revenue mix: Revenue contribution from Global generics stood at 75.6% (78.7% in Q4FY18), Pharmaceutical Services and Active Ingredients (PSAI) at 16.8% (17.7%) and Proprietary Products & Others at 7.5% (3.6%), for the quarter.
Global Generics: Revenue from Europe (primarily includes Germany and UK), India and North America were up 12%, 6% and 3% yoy respectively. Emerging markets, which includes Russia, other CIS countries, Romania and Rest of the World markets, reported 27% yoy growth for the quarter.
PSAI reported 8% yoy revenue growth for the quarter and revenue from Proprietary Products & Others jumped by 139% yoy.
Company’s focus continues on building complex generics, bio-similars and differentiated products pipeline. Thus, R&D expenses for the quarter stood at Rs370cr, 9.1% of net sales.
Dr Reddys Laboratories Ltd is currently trading at Rs. 2,748.10, down by 56.4 points or 2.01% from its previous closing of Rs. 2,804.50 on the BSE.
The scrip opened at Rs. 2,790 and has touched a high and low of Rs. 2,811.65 and Rs. 2,668.80 respectively. So far 12,17,920 (NSE+BSE) shares were traded on the counter. The stock is currently trading above its 50 DMA.
Please use the temporary password sent on your email id or mobile no.
Update Mobile no.
Why you need to update your Mobile number ?
By providing verified mobile number we provide more exclusive information in the website.
Update Mobile no.
Terms & Conditions
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in National Do Not Call Registry as laid down by Telecom Regulatory Authority of India will not be applicable for such information/ communication.